Type to search

Diseases News Medical Research News World Health

WHO Authorizes Bharat Biotech’s COVAXIN For Emergency Use Listing

COVAXIN

Read in: English

Key Points

  • Emergency Use Listing by WHO will expedite global access and availability of COVAXIN worldwide.
  • The WHO’s Emergency Use Listing (EUL) for COVAXIN facilitates countries to expedite their regulatory approval processes to introduce and administer India’s indigenously made COVID-19 vaccine developed and manufactured by Bharat Biotech.
  • It also allows procurement by UNICEF, PAHO, and the GAVI COVAX facility for distribution to countries in need.

Bharat Biotech, a global leader in vaccine development and innovation, today announced that COVAXIN, India’s first indigenous Covid-19 vaccine, has been granted Emergency Use Listing by the World Health Organization (WHO). This vaccine is a whole virion-inactivated vaccine against SARS-CoV2, developed in partnership with ICMR and NIV, Pune.

The emergency use listing (EUL) procedure assesses the suitability of novel health products during public health emergencies, with the objective of providing rapid access to medicines, vaccines and diagnostics, while adhering to stringent criteria of safety, efficacy and quality.

With validation from the WHO, countries can now expedite their regulatory approval processes to import and administer COVAXIN. Furthermore, UNICEF, Pan-American Health Organization (PAHO), GAVI COVAX facility, will be able to procure COVAXIN for distribution to countries worldwide. This will enable them to secure the critical supply needed to meet the requirements of priority populations, thereby ensuring equitable access.

Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, “Validation by WHO is a very significant step towards ensuring global access to India’s widely administered, safe, and efficacious COVAXIN. As an organization, we have focused on maintaining stringent quality and safety standards that meet rigorous assessment, and scientific standards established by WHO, as a result, many of our vaccines have received WHO prequalification. The EUL authorization for COVAXIN will enable us to contribute to accelerating the equitable access of Covid-19 vaccine, and the access to our vaccine globally thereby addressing the current public health emergency.”


Read also: WHO: Less than 10% of African Countries To Hit Key COVID-19 Vaccination Goal


The phase 3 trial data for COVAXIN was available during June 2021. The World Health Organisation (WHO) Emergency Use Listing (EUL) process commenced on July 6, 2021, with rolling data submission. The Strategic Advisory Group of Experts on Immunization (SAGE) of WHO had reviewed COVAXIN data on October 5 in a meeting and granted EUL for COVAXIN today (November 3, 2021).

COVAXIN has been specifically designed to meet the needs of global distribution chains, the requirements for which are more critical in low- and middle-income countries. It has been formulated to enable shipping and long-term storage at 2-8ºC. It is also formulated to adhere to a multi-dose vial policy, thereby reducing open vial wastage, saving money to procurement agencies and governments alike.

Mrs. Suchitra Ella, Joint Managing Director, Bharat Biotech, said, “The WHO nod for COVAXIN is a validation of the tremendous effort made by everyone at Bharat Biotech and our partners. It is also an opportunity for us to create meaningful impact at a global level. Such an impact can only be orchestrated when multiple stakeholders come together to work towards a common goal. COVAXIN is a great example of a successful public-private partnership in developing a world-class COVID-19 vaccine.  We look forward to playing a larger role to help the efforts by both the developed and developing nations to control the pandemic.”

Tags:

Leave a Comment

Your email address will not be published. Required fields are marked *